PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-5.57%
Revenue decline while Medical - Pharmaceuticals median is 1.29%. Seth Klarman would investigate if market share loss is temporary.
-5.41%
Cost reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive advantage potential.
-6.27%
Gross profit decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
-0.74%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.78%
Other expenses change of 16.78% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
4.90%
Operating expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 0.50%. Jim Chanos would check for waste.
-3.97%
Total costs reduction while Medical - Pharmaceuticals median is 0.95%. Seth Klarman would investigate advantages.
-6.25%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
16.15%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 1.47%. Jim Chanos would check for overinvestment.
-28.21%
EBITDA decline while Medical - Pharmaceuticals median is 3.55%. Seth Klarman would investigate causes.
-23.98%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.07%. Seth Klarman would investigate causes.
-30.80%
Operating income decline while Medical - Pharmaceuticals median is 5.18%. Seth Klarman would investigate causes.
-26.71%
Operating margin decline while Medical - Pharmaceuticals median is 0.81%. Seth Klarman would investigate causes.
29.92%
Other expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 0.19%. Jim Chanos would check for issues.
-27.70%
Pre-tax income decline while Medical - Pharmaceuticals median is 4.86%. Seth Klarman would investigate causes.
-23.43%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.15%. Seth Klarman would investigate causes.
-26.68%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-28.44%
Net income decline while Medical - Pharmaceuticals median is 6.11%. Seth Klarman would investigate causes.
-24.22%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-28.45%
EPS decline while Medical - Pharmaceuticals median is 8.12%. Seth Klarman would investigate causes.
-28.45%
Diluted EPS decline while Medical - Pharmaceuticals median is 7.98%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.